ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Celgene will pay Prothena $100 million up front as part of a pact to develop antibodies against three neuroscience drug targets: tau, a protein linked to Alzheimer’s disease; TDP-43, a protein implicated in amyotrophic lateral sclerosis; and an undisclosed target. The deal, which also calls for Celgene to take an equity stake in Prothena worth $50 million, comes at a time when Celgene is trying to bolster its neurodegenerative disease pipeline. Celgene can license the U.S. rights to drug candidates after Phase I studies.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter